WILMINGTON, Mass.--(BUSINESS WIRE)--Sirtex, a leading developer of targeted and innovative cancer therapies, announces the launch of a clinical trial evaluating the effect of treatment with SIR-Spheres® microspheres on the survival of patients with unresectable hepatocelluar carcinoma (HCC). Ravi Murthy, M.D., interventional radiologist with the University of Texas M.D. Anderson Cancer Center, and T. Clark Gamblin, M.D., surgical oncologist with the University of Pittsburgh Medical Center’s Liver Cancer Center, will serve as coordinating investigators for the study.
